Navigation Links
Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
Date:1/22/2008

Company Files Additional Data to the NEBIDO NDA

PDUFA Date Expected to Remain June 27, 2008

LEXINGTON, Mass., Jan. 22 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced additional positive results from its Phase III program for NEBIDO (testosterone undecanoate), a long-acting injectable testosterone therapy under development for the treatment of male hypogonadism. The trial data announced today has been filed with the U.S. Food and Drug Administration (FDA) as an addition to data contained in the Company's existing New Drug Application (NDA) that was originally filed on August 28, 2007. Based on recent conversations with the FDA, the Company anticipates that the FDA Prescription Drug User Fee Act (PDUFA) target action date for NEBIDO will remain June 27, 2008.

The dosing regimen for NEBIDO submitted in the original NDA was 1000 mg given every 12 weeks, and as announced previously, achieved all of the primary endpoints according to the FDA criteria for approvability. The Company has been exploring additional dosage regimens to determine if it is possible to achieve a more rapid onset of steady state testosterone pharmacokinetics and still satisfy each of the FDA pre-specified criteria for approvability. This recently completed Phase III trial, announced today, studied a new treatment regimen in which hypogonadal men were given an initial injection of 750 mg of NEBIDO, followed 4-weeks later by an additional 750 mg loading injection and then 750 mg injections every 10-weeks thereafter.

The data from this recently completed Phase III trial demonstrated a highly effective treatment regimen. In the trial, NEBIDO demonstrated a rapid achievement of steady state
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Submission of New Drug Application
3. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Reportlinker.com announces that a ... catalogue: mHealth and Home Monitoring – ... Executive summary mHealth can ... better outcomes, decreased costs and improved sustainability of ... is still in an early stage, but on ...
(Date:7/30/2014)... brand ambassadors Fred Funk and Hal Sutton ... near Minneapolis, MN , which begins Friday at ... the official joint replacement products company of the PGA TOUR and ... through Sunday, August 3 rd , fans will be able to ... in the Pioneer Press Expo tent located near the clubhouse and ...
(Date:7/30/2014)... Calif. , July 30, 2014 Silicon ... released a study today that examines the ... and medical device companies.  According to the annual report ... the biggest potential returns since SVB started tracking the ... of the IPO.  Built on solid healthcare M&A activity ...
Breaking Medicine Technology:mHealth and Home Monitoring - 6th Edition 2mHealth and Home Monitoring - 6th Edition 3mHealth and Home Monitoring - 6th Edition 4mHealth and Home Monitoring - 6th Edition 5mHealth and Home Monitoring - 6th Edition 6mHealth and Home Monitoring - 6th Edition 7mHealth and Home Monitoring - 6th Edition 8mHealth and Home Monitoring - 6th Edition 9mHealth and Home Monitoring - 6th Edition 10mHealth and Home Monitoring - 6th Edition 11Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3
... findings presented today show that CONCERTA® (OROS® methylphenidate ... medication with data that demonstrate a significant treatment ... 12.5 hours in children with Attention Deficit Hyperactivity ... medical condition characterized by inattention, hyperactivity and impulsivity(1) ...
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), a ... announced unaudited financial results for the three months ended ... September 30, 2009 , As of September 30, ... equivalents and an additional $50.9 million in investment securities, ...
Cached Medicine Technology:CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 2CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 3CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 4CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 5CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 6CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 7Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 2Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 3Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 4Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 5Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 6Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 7Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 8Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 9Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 10
(Date:7/30/2014)... Alan Mozes HealthDay Reporter ... to help their preschooler shed excess pounds may want to ... whose parents joined them in a supervised behavioral modification program ... a traditional child-only program (an average difference of about four ... almost 15 pounds over two years, according to the study. ...
(Date:7/30/2014)... from the Church of Scientology of Denmark have joined ... distribution of Truth About Drugs education booklets. ... the famous Copenhagen walking street. Popular with tourists ... some quarter of a million people stroll down the ... activities are part of a coordinating effort by Scientologists ...
(Date:7/30/2014)... to fuel cancer as well as evolutionary changes in ... that occur randomly throughout the genome. , However, recent ... formation of multiple mutations that arise simultaneously and in ... mutations are frequently found in regions where chromosomal rearrangements ... Cell Reports , may one day lead to ...
(Date:7/30/2014)... Lexington, MA (PRWEB) July 30, 2014 ... provider of authentication, access management and secure communications ... Imprivata OneSign ® is the most widely ... using McKesson Paragon or Horizon electronic medical records ... (an increase of about 11 percent in the ...
(Date:7/30/2014)... IN (PRWEB) July 30, 2014 ... the opening of its new Carmel office on July ... staff will finally be moving to the state-of-the-art suite, ... cozy and innovative space will allow for one-on-one patient ... cosmetic surgery experience. , Dr. Hamilton’s new office-suite ...
Breaking Medicine News(10 mins):Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 2Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 3Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 4Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2
... , , PASADENA, ... AIMM) today announced its licensee, BioMS Medical Corp., and ... meet the primary endpoint of delaying disease progression, as ... the two-year Phase III trial in patients with secondary ...
... EATONTOWN, N.J., July 30 Osteotech, Inc. (Nasdaq: ... for regenerative healing, announced today that its management team is scheduled ... Healthcare Conference at the Millennium Broadway Hotel in New York on ... A live, listen-only webcast of the presentation can be ...
... , , , , ... Corp. (Nasdaq: WBMD ) today announced financial results for the three ... to deliver strong results again this quarter. WebMD,s advertising revenue grew by 18% ... companies in the health and wellness markets," said Wayne Gattinella, President and CEO. ...
... , WASHINGTON, July 30 An estimated 700,100 residents ... a House health reform bill, according to state-specific analysis ... released this week by The Heritage Foundation . ... Lewin Group , a highly respected health care policy and ...
... NOVATO, Calif., July 30, BioMarin Pharmaceutical Inc. (Nasdaq: ... has issued patents covering stable tablet formulation and the approved once ... phenylketonuria (PKU). The patent for stable tablet formulation expires in ... in 2024. , , "We believe the issuance ...
... researchers say , THURSDAY, July 30 (HealthDay News) -- ... vaccine activates the immune system against the virus appear ... study finds. , According to Dutch researchers led by ... immune system goes on alert against the seasonal flu ...
Cached Medicine News:Health News:Clinical Trial by Licensee Does Not Meet Primary Endpoint 2Health News:WebMD Announces Second Quarter Financial Results 2Health News:WebMD Announces Second Quarter Financial Results 3Health News:WebMD Announces Second Quarter Financial Results 4Health News:WebMD Announces Second Quarter Financial Results 5Health News:WebMD Announces Second Quarter Financial Results 6Health News:WebMD Announces Second Quarter Financial Results 7Health News:WebMD Announces Second Quarter Financial Results 8Health News:WebMD Announces Second Quarter Financial Results 9Health News:WebMD Announces Second Quarter Financial Results 10Health News:WebMD Announces Second Quarter Financial Results 11Health News:WebMD Announces Second Quarter Financial Results 12Health News:WebMD Announces Second Quarter Financial Results 13Health News:WebMD Announces Second Quarter Financial Results 14Health News:WebMD Announces Second Quarter Financial Results 15Health News:WebMD Announces Second Quarter Financial Results 16Health News:WebMD Announces Second Quarter Financial Results 17Health News:WebMD Announces Second Quarter Financial Results 18Health News:WebMD Announces Second Quarter Financial Results 19Health News:Thousands of Nebraskans Could Lose Private Insurance, Study Shows 2Health News:Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen for Kuvan 2Health News:Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen for Kuvan 3Health News:Flu Shot May Be Less Effective in Those With Lupus 2
The MPF cup is specifically designed to achieve high primary stability, a critical factor for long term success....
The Trilogy system builds on the success of the Harris/Galante Porous and HGP II cups by combining proven features with new technology designed to inhibit the formation and migration of polyethylene ...
For primary and revision cases...
The Protract stem offers a press-fit option which will allow choice of standard or lateralized neck offsets while keeping a consistent leg length....
Medicine Products: